Adimab, a monoclonal and bispecific antibody discovery company, and Chinese privately-held biopharmaceutical company Innovent have partnered to discover, develop and commercialise an antibody-based therapeutic.

According to the deal, Adimab will leverage the antibody discovery and optimisation platform in identifying a fully-human therapeutic antibody against an Innovent selected target.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Initial product development activities such as cell line development, formulation, manufacturing and clinical trials will be coordinated by Innovent, while the parties will jointly coordinate the development, manufacture and commercialisation of the therapeutic antibody.

"Adimab will leverage the antibody discovery and optimisation platform in identifying a fully-human therapeutic antibody against an Innovent selected target."

Adimab chief executive officer Tillman Gerngross said, "They have built a remarkable manufacturing infrastructure and we are confident in their ability to develop attractive programmes for the Chinese market."

For the discovery and optimisation of the therapeutic leads, Innovent will compensate Adimab, which will reimburse Innovent for specific development costs.

See Also:

The rights to develop and commercialise the therapeutic programme will be retained by Innovent in China, with sales-based royalties owed to Adimab, which will retain rights for commercialisation in the US, Europe and Japan with product sales-based royalties owed to Innovent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Innovent chief executive officer Michael Yu said, "We feel that combining the Adimab platform with Innovent’s strong development and manufacturing capabilities will help us to rapidly build a strong therapeutic pipeline and commercial presence in China."

Meanwhile, Adimab has achieved technical milestones from its ongoing collaborations with Eli Lilly and Company, Gilead and Kyowa Hakko Kirin.